Tsimikas, Sotirios

A Test in Context: Lipoprotein(a)

Tsimikas, S. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 1,137

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 1,094

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 754

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 669

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 573

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 572

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 564

Complement factor H binds malondialdehyde epitopes and protects from oxidative stress

Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P. N., Issa, P. C., Cano, M., Brandstätter, H., Tsimikas, S., Skerka, C., et al. (2011) · Nature

Complement system in diseasesRetinal Diseases and Treatments

Cited by 533

Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice

Que, X., Hung, M.-Y., Yeang, C., Gonen, A., Prohaska, T. A., Sun, X., Diehl, C., Määttä, A., Gaddis, D. E., Bowden, K., et al. (2018) · Nature

Atherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

Cited by 529

Statin therapy increases lipoprotein(a) levels

Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 512

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 460

Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis

Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology

Cardiac Valve Diseases and TreatmentsAtherosclerosis and Cardiovascular Diseases

Cited by 417

Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)

Willeit, P., Kiechl, S., Kronenberg, F., Witztum, J. L., Santer, P., Mayr, M., Xu, Q., Mayr, A., Willeit, J., & Tsimikas, S. (2014) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 286

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 279

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 271

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 262

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 232

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 231

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

Tsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G. (2004) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 225

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 214

Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis

Willeit, P., Raschenberger, J., Heydon, E. E., Tsimikas, S., Haun, M., Mayr, A., Weger, S., Witztum, J. L., Butterworth, A. S., Willeit, J., et al. (2014) · PLoS ONE

Telomeres, Telomerase, and SenescenceGenetic Associations and Epidemiology

Cited by 211

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 210

Apolipoprotein C-III: from pathophysiology to pharmacology

Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 182

Lipid-Lowering Agents: Targets Beyond PCSK9

Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 171